Under construction – not a live service
Sign in
Taking people in NetherlandsNo phase

Compares continuing or pausing blood thinners before heart procedures in atrial fibrillation

Tests whether keeping or pausing a blood thinner before coronary heart procedures is safe.

Key facts

Who runs it
Zuyderland Medisch Centrum
Where
Heerlen, NetherlandsSee the site
Trial code
Registry title
Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention
Status
Recruiting
People taking part
1,270 people, planned
Started
1 Sept 2022
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Uninterrupted DOAC use
  • Interrupted DOAC use
Record updated
29 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who take a direct oral anticoagulant (DOAC) blood thinner and are planned for an elective coronary angiography or stent procedure (PCI).

Age
Older than 18 years
Sex
All sexes can join
Disease stage
People who take a DOAC and have a planned (elective) coronary angiography (ICA) or PCI. People who first came in with acute coronary syndrome cannot join.
Earlier treatment
Must be taking a DOAC. Cannot have had a major surgery within 30 days before the procedure.
Biomarker or test result
Creatinine clearance (a kidney test) must not be below 30 mL/min. Liver test ALT must not be above 3 times the upper limit of normal.

Main reasons for not taking part

  • First presenting with acute coronary syndrome (STEMI, NSTEMI, UA)
  • Creatinine clearance below 30 mL/min
  • Higher bleeding risk, such as GI bleeding in the previous 6 months or a chronic bleeding disorder
  • Current pregnancy or breast-feeding
  • Taking part in another clinical trial at the same time

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Patients aged >18 years using DOAC and undergoing elective ICA or PCI
  • Provided signed informed consent

Who cannot take part

  • Patients initially presenting with Acute Coronary Syndrome (STEMI, NSTEMI, UA)
  • Calculated creatinine clearance <30 mL/min
  • History or condition associated with increased bleeding risk, as listed below:; Major surgical procedure within 30 days before the procedure; Known inaccessible radial artery during previous procedure; History of GI bleeding in the previous 6 months; History of intracranial, intraocular, spinal, or atraumatic intra-articular bleeding; Chronic bleeding disorder; Known intracranial neoplasm, arteriovenous malformation, or aneurysm; Known anemia with last measured haemoglobin value <6 mmol/L [9.67 g/dL]; Current pregnancy or breast-feeding; Known significant liver disease (e.g., acute clinical hepatitis, chronic active hepatitis, cirrhosis), or Alanine aminotransferase (ALT) >3 x the upper limit of normal
  • Patients <18 years old
  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • Any of the following:
  • Patients simultaneously participating in another clinical trial
  • Participation in another clinical trial

Where in Netherlands

  • Zuyderland MCHeerlen, NetherlandsContact: Sanne Janssen, MScTaking people

About the trial

What the trial wants to find out

A prospective, multicenter, 1:1 randomized, investigator initiated study. Goal of this study is to examine the safety of uninterrupted periprocedural DOAC use.

The 2 groups in the trial

  • Interrupted DOAC use (group 1)Existing treatment, for comparison

    Patients in group 1 will receive standard care. Therefore, DOAC use will be interrupted at least 24 hours in advance of ICA or PCI. Based on the renal clearance, last DOAC intake may be extended to 48 hours prior to the procedure \[Table 2\]. After the procedure, patients will continue using their DOAC as usual.

    Treatment: Interrupted DOAC use

  • Uninterrupted DOAC use (group 2)Treatment being tested

    In group 2, all patients will continue to use their specific DOAC as usual. This means that no adjustments of DOAC use will be made before and after ICA or PCI. After the procedure patients will continue to use DOAC from the next planned dose.

    Treatment: Uninterrupted DOAC use

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention
Plain-language title
Compares continuing or pausing blood thinners before heart procedures in atrial fibrillationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
29 May 2026